EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pharmacological METTL3 inhibition attenuates HIV-1 latency reversal in CD4 + T cells

Tarun Mishra iD, Avary Edwards iD, Li Wu iD

Antimicrobial Agents and Chemotherapy · 2026

DOI: 10.1128/aac.00400-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Tarun Mishra und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Carver College of Medicine, The University of Iowa, Iowa City, Iowa, USA. Hauptthemen laut MEDLINE: HIV-1, CD4-Positive T-Lymphocytes, Virus Latency, Methyltransferases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIAID NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

N 6 -methyladenosine (m 6 A) is a major epitranscriptomic modification that regulates RNA metabolism and affects the replication and latency reversal of human immunodeficiency virus type 1 (HIV-1) in cells. Methyltransferase-like 3 (METTL3) is the principal catalytic enzyme responsible for m 6 A deposition, and its pharmacological inhibition has emerged as a potential therapeutic strategy for cancer and viral infections. However, the relative potency of METTL3 inhibitors in reducing m 6 A levels and their effects on HIV-1 latency reversal remain undefined. Here, we compared three commercially available METTL3 inhibitors (STM2457, STM3006, and STC-15) to evaluate their ability to reduce RNA m 6 A levels, suppress HIV-1 latency reversal, and affect cell viability in latently infected J-Lat cells and primary CD4 + T cells. In J-Lat cells, STM3006 and STC-15 were more potent than STM2457 in reducing RNA m 6 A levels at 24 and 48 h post-treatment, as reflected by lower half-maximal inhibitory concentrations (IC 50 ). However, STM3006 and STC-15 exhibited significant cytotoxicity at concentrations above 2 µM at 48 h post-treatment, whereas STM2457 displayed minimal toxicity across all tested doses. In primary CD4 + T cells from three healthy donors, all three inhibitors reduced RNA m 6 A levels except STC-15 treatment of one donor’s cells, while STM3006 induced significant cytotoxicity at 24 h post-treatment. Notably, reduced RNA m 6 A levels correlated with diminished HIV-1 latency reversal in both J-Lat cells and a primary central memory CD4 + T cell model. Together, these findings demonstrate differential potency and cytotoxicity among METTL3 inhibitors and support a critical role for m 6 A RNA modification in regulating HIV-1 latency reversal.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1CD4-Positive T-LymphocytesVirus LatencyMethyltransferasesHumansAdenosineRNA MethylationVirus ReplicationRNA, ViralCell LineEpitranscriptomeCell Survival

Stichwörter der Autor:innen

CD4+T cellsHIV-1METTL3 inhibitorslatency reversalm6A modification

Substanzen

MethyltransferasesMETTL3 protein, humanAdenosineN-methyladenosineRNA, Viral

Autor:innen und Institutionen

  • Department of Microbiology and Immunology, Carver College of Medicine, The University of Iowa, Iowa City, Iowa, USA.
  • Biomedical Sciences Graduate Program, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA.

ORCID-Profile: Tarun Mishra, Avary Edwards, Li Wu

Förderung

  • NCI NIH HHS
  • NIAID NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Mishra, T., Edwards, A., & Wu, L. (2026). Pharmacological METTL3 inhibition attenuates HIV-1 latency reversal in CD4 + T cells. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00400-26

Vancouver

Mishra T, Edwards A, Wu L. Pharmacological METTL3 inhibition attenuates HIV-1 latency reversal in CD4 + T cells. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.00400-26

BibTeX
@article{Mishra2026,
  author = {Mishra, Tarun and Edwards, Avary and Wu, Li},
  title = {Pharmacological METTL3 inhibition attenuates HIV-1 latency reversal in CD4 + T cells},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  doi = {10.1128/aac.00400-26}
}
Kostenlos starten →